Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors

10 May 2023

Abstract excerpt

Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency. However, many patients without apparent HR defects also respond well to PARP inhibitors/cisplatin. The biomarker responsible for this mechanism remains unclear. Here, we identified a set of ribosomal genes that predict response to PARP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37160887
DOI: 10.1038/s41392-023-01401-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumorsPMID 37160887Read ↗

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineSemantic proximity Read ↗

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitorsSemantic proximity Read ↗

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

Current status of poly(ADP-ribose) polymerase inhibitors and future directionsSemantic proximity Read ↗

A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.Semantic proximity Read ↗

PARP Inhibitors Resistance: Mechanisms and PerspectivesSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivitySemantic proximity Read ↗

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read ↗

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity Read ↗

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.